United States Biotechnology & Medical Research

Editas Medicine Inc (EDIT)

Track

Over the past 90 days, Editas Medicine Inc. insiders have engaged in five transactions, all of which were sales, resulting in a net negative value of approximately $86,314. Key executives, including the CEO and CFO, have consistently sold shares. These transactions follow a period where the stock price declined by 16.5% and the company reported a miss in its latest earnings report.
Ticker: EDIT Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Editas Medicine Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Burkly Linda
Officer
1 sale — total 100,000 USD
Proposed sale 27 Jul 2026
Value US$2,810,159.55 | Price 494.30 | Shares 90,580
Sale 3 Jun 2026
Value US$1,194,234.01 | Price 307.61 | Shares 39,236
Sale 3 Jun 2026
Value US$722,714.52 | Price 280.57 | Shares 69,034
Proposed sale 3 Jun 2026
Value US$46,200.00 | Price 3.08 | Shares 15,000
Sale 3 Jun 2026
Value US$1,974.50 | Price 2.70 | Shares 731
Sale 3 Jun 2026
Value US$1,253.26 | Price 2.70 | Shares 464
Sale 3 Mar 2026
Value US$10,894.26 | Price 2.02 | Shares 5,394
Proposed sale 3 Mar 2026
Value US$11,340.00 | Price 1.89 | Shares 6,000
Sale 3 Mar 2026
Value US$957.48 | Price 2.02 | Shares 474
Sale 3 Mar 2026
Value US$1,512.68 | Price 2.02 | Shares 749
Sale 3 Dec 2025
Value US$1,535.16 | Price 2.15 | Shares 713
Sale 3 Dec 2025
Value US$12,063.82 | Price 2.15 | Shares 5,603
Proposed sale 3 Dec 2025
Value US$17,500.00 | Price 2.50 | Shares 7,000
Sale 3 Dec 2025
Value US$992.58 | Price 2.15 | Shares 461
Planned sale 3 Sep 2025
Value US$1,843.23 | Price 2.60 | Shares 710
Proposed sale 3 Sep 2025
Value US$2,184.00 | Price 2.73 | Shares 800
Sale 3 Sep 2025
Value US$14,517.39 | Price 2.60 | Shares 5,592
Proposed sale 3 Sep 2025
Value US$19,110.00 | Price 2.73 | Shares 7,000
Sale 3 Sep 2025
Value US$1,189.01 | Price 2.60 | Shares 458
Sale 7 Aug 2025
Value US$1,751.82 | Price 2.58 | Shares 679
Sale 31 Jul 2025
Value US$12,756.92 | Price 2.49 | Shares 5,121
Proposed sale 31 Jul 2025
Value US$25,950.00 | Price 3.46 | Shares 7,500
Sale 3 Jun 2025
Value US$26,195.57 | Price 1.72 | Shares 15,192
Proposed sale 3 Jun 2025
Value US$37,400.00 | Price 1.87 | Shares 20,000
Sale 3 Jun 2025
Value US$1,251.84 | Price 1.72 | Shares 726
Sale 3 Jun 2025
Value US$768.90 | Price 1.72 | Shares 446
Sale 4 Mar 2025
Value US$4,945.63 | Price 1.71 | Shares 2,891
Sale 4 Mar 2025
Value US$28,452.36 | Price 1.71 | Shares 16,632
Sale 4 Mar 2025
Value US$7,029.68 | Price 1.71 | Shares 4,109
Proposed sale 3 Mar 2025
Value US$65,100.00 | Price 1.86 | Shares 35,000
Proposed sale 3 Mar 2025
Value US$14,880.00 | Price 1.86 | Shares 8,000
Proposed sale 3 Mar 2025
Value US$11,160.00 | Price 1.86 | Shares 6,000
Sale 3 Dec 2024
Value US$3,361.23 | Price 2.08 | Shares 1,618
Sale 3 Dec 2024
Value US$1,123.77 | Price 2.08 | Shares 541
Sale 4 Sep 2024
Value US$1,773.99 | Price 3.42 | Shares 518
Sale 4 Sep 2024
Value US$5,325.41 | Price 3.42 | Shares 1,555
Proposed sale 3 Sep 2024
Value US$11,760.00 | Price 3.92 | Shares 3,000
Proposed sale 3 Sep 2024
Value US$3,920.00 | Price 3.92 | Shares 1,000
Sale 25 Jul 2024
Value US$64,369.82 | Price 5.42 | Shares 11,886
Proposed sale 25 Jul 2024
Value US$145,860.00 | Price 5.61 | Shares 26,000
Sale 19 Jul 2024
Value US$34,455.87 | Price 5.21 | Shares 6,619
Proposed sale 19 Jul 2024
Value US$78,540.00 | Price 5.61 | Shares 14,000
Sale 4 Jun 2024
Value US$2,808.25 | Price 5.50 | Shares 511
Sale 4 Jun 2024
Value US$66,996.86 | Price 5.50 | Shares 12,191
Proposed sale 3 Jun 2024
Value US$127,680.00 | Price 5.32 | Shares 24,000
Proposed sale 3 Jun 2024
Value US$5,320.00 | Price 5.32 | Shares 1,000
Sale 20 May 2024
Value US$125,404.39 | Price 5.61 | Shares 22,337
Proposed sale 17 May 2024
Value US$256,950.00 | Price 5.71 | Shares 45,000
Buy 13 May 2024
Value US$253,867.50 | Price 5.64 | Shares 45,000
Buy 13 May 2024
Value US$253,867.50 | Price 5.64 | Shares 45,000
Sale 5 Mar 2024
Value US$732,884.17 | Price 9.42 | Shares 77,824
Sale 4 Mar 2024
Value US$191,425.46 | Price 9.42 | Shares 20,327
Proposed sale 4 Mar 2024
Value US$1,240,400.00 | Price 8.86 | Shares 140,000
Sale 5 Dec 2023
Value US$1,122.41 | Price 10.90 | Shares 103
Sale 14 Nov 2023
Value US$5,705.67 | Price 8.21 | Shares 695
Sale 7 Nov 2023
Value US$1,167.60 | Price 8.40 | Shares 139
Sale 6 Sep 2023
Value US$908.46 | Price 8.82 | Shares 103
Sale 11 Aug 2023
Value US$6,032.64 | Price 8.59 | Shares 702
Sale 8 Aug 2023
Value US$1,182.99 | Price 8.39 | Shares 141
Sale 19 Jul 2023
Value US$37,989.60 | Price 8.80 | Shares 4,317
Sale 5 Jun 2023
Value US$997.82 | Price 9.50 | Shares 105
Sale 5 Jun 2023
Value US$61,637.76 | Price 9.50 | Shares 6,486
Proposed sale 5 Jun 2023
Value US$78,030.00 | Price 9.18 | Shares 8,500
Sale 11 May 2023
Value US$9,368.53 | Price 9.87 | Shares 949
Sale 11 May 2023
Value US$6,594.50 | Price 9.87 | Shares 668
Proposed sale 11 May 2023
Value US$10,845.12 | Price 3.62 | Shares 3,000
Sale 9 May 2023
Value US$1,283.85 | Price 9.51 | Shares 135
Sale 3 Mar 2023
Value US$1,635.76 | Price 8.89 | Shares 184
Sale 3 Mar 2023
Value US$897.89 | Price 8.89 | Shares 101
Sale 13 Feb 2023
Value US$31,963.15 | Price 9.67 | Shares 3,307
Sale 13 Feb 2023
Value US$41,435.14 | Price 9.67 | Shares 4,287
Sale 13 Feb 2023
Value US$26,966.19 | Price 9.67 | Shares 2,790
Sale 7 Feb 2023
Value US$3,840.60 | Price 11.10 | Shares 346
Sale 10 Jan 2023
Value US$14,296.50 | Price 8.16 | Shares 1,752
Sale 5 Dec 2022
Value US$1,043.46 | Price 10.23 | Shares 102
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-21 2026-07-27 PrS Proposed sale
4.1
Burkly Linda

Officer

Officer
90,580
494.30
US$2,810,160 		90,580 494.30 US$2,810,160
2026-06-05 2026-06-03 S Sale
4.3
O'Neill Gilmore Neil

CEO

Executive Director
39,236 -49.5%
307.61
US$1,194,234 		39,236 -49.5% 307.61 US$1,194,234
2026-06-05 2026-06-03 S Sale
4.3
O'Neill Gilmore Neil

CEO

Executive Director
69,034 -38.4%
280.57
US$722,715 		69,034 -38.4% 280.57 US$722,715
2026-06-05 2026-06-03 S Sale
4.1
Burkly Linda

EVP, CHIEF SCIENTIFIC OFFICER

Officer
731 -1.1%
2.70
US$1,975 		731 -1.1% 2.70 US$1,975
2026-06-05 2026-06-03 S Sale
2.1
Parison Amy

SVP, Chief Financial Officer

Officer
464 -3.0%
2.70
US$1,253 		464 -3.0% 2.70 US$1,253
2026-05-29 2026-06-03 PrS Proposed sale
4.3
O'Neill Gilmore Neil

Officer; Director

Executive Director
15,000
3.08
US$46,200 		15,000 3.08 US$46,200
2026-03-04 2026-03-03 S Sale
4.3
O'Neill Gilmore Neil

CEO

Executive Director
5,394 -2.0%
2.02
US$10,894 		5,394 -2.0% 2.02 US$10,894
2026-03-04 2026-03-03 S Sale
2.1
Parison Amy

SVP, Chief Financial Officer

Officer
474 -3.0%
2.02
US$957 		474 -3.0% 2.02 US$957
2026-03-04 2026-03-03 S Sale
4.1
Burkly Linda

EVP, CHIEF SCIENTIFIC OFFICER

Officer
749 -1.1%
2.02
US$1,513 		749 -1.1% 2.02 US$1,513
2026-02-27 2026-03-03 PrS Proposed sale
4.3
O'Neill Gilmore Neil

Officer; Director

Executive Director
6,000
1.89
US$11,340 		6,000 1.89 US$11,340
2025-12-04 2025-12-03 S Sale
4.1
Burkly Linda

EVP, CHIEF SCIENTIFIC OFFICER

Officer
713 -1.0%
2.15
US$1,535 		713 -1.0% 2.15 US$1,535
2025-12-04 2025-12-03 S Sale
4.3
O'Neill Gilmore Neil

CEO

Executive Director
5,603 -2.0%
2.15
US$12,064 		5,603 -2.0% 2.15 US$12,064
2025-12-04 2025-12-03 S Sale
2.1
Parison Amy

SVP, Chief Financial Officer

Officer
461 -2.8%
2.15
US$993 		461 -2.8% 2.15 US$993
2025-12-01 2025-12-03 PrS Proposed sale
4.3
O'Neill Gilmore Neil

Officer; Director

Executive Director
7,000
2.50
US$17,500 		7,000 2.50 US$17,500
2025-09-04 2025-09-03 PlS Planned sale
4.1
Burkly Linda

EVP, CHIEF SCIENTIFIC OFFICER

Officer
710 -1.0%
2.60
US$1,843 		710 -1.0% 2.60 US$1,843
2025-09-04 2025-09-03 S Sale
4.3
O'Neill Gilmore Neil

CEO

Executive Director
5,592 -2.0%
2.60
US$14,517 		5,592 -2.0% 2.60 US$14,517
2025-09-04 2025-09-03 S Sale
2.1
Parison Amy

SVP, Chief Financial Officer

Officer
458 -2.7%
2.60
US$1,189 		458 -2.7% 2.60 US$1,189
2025-08-29 2025-09-03 PrS Proposed sale
4.3
O'Neill Gilmore Neil

Officer; Director

Executive Director
7,000
2.73
US$19,110 		7,000 2.73 US$19,110
2025-08-29 2025-09-03 PrS Proposed sale
4.1
Burkly Linda

Officer

Officer
800
2.73
US$2,184 		800 2.73 US$2,184
2025-08-08 2025-08-07 S Sale
2.1
Parison Amy

SVP, Chief Financial Officer

Officer
679 -3.9%
2.58
US$1,752 		679 -3.9% 2.58 US$1,752
2025-08-04 2025-07-31 S Sale
4.1
Burkly Linda

EVP, CHIEF SCIENTIFIC OFFICER

Officer
5,121 -7.4%
2.49
US$12,757 		5,121 -7.4% 2.49 US$12,757
2025-07-30 2025-07-31 PrS Proposed sale
4.1
Burkly Linda

Officer

Officer
7,500
3.46
US$25,950 		7,500 3.46 US$25,950
2025-06-04 2025-06-03 S Sale
4.3
O'Neill Gilmore Neil

CEO

Executive Director
15,192 -5.1%
1.72
US$26,196 		15,192 -5.1% 1.72 US$26,196
2025-06-04 2025-06-03 S Sale
4.1
Burkly Linda

EVP, CHIEF SCIENTIFIC OFFICER

Officer
726 -1.0%
1.72
US$1,252 		726 -1.0% 1.72 US$1,252
2025-06-04 2025-06-03 S Sale
2.1
Parison Amy

SVP, Chief Financial Officer

Officer
446 -2.5%
1.72
US$769 		446 -2.5% 1.72 US$769
2025-06-02 2025-06-03 PrS Proposed sale
4.3
O'Neill Gilmore Neil

Officer; Director

Executive Director
20,000
1.87
US$37,400 		20,000 1.87 US$37,400
2025-03-05 2025-03-04 S Sale
4.1
Burkly Linda

EVP, CHIEF SCIENTIFIC OFFICER

Officer
2,891 -4.0%
1.71
US$4,946 		2,891 -4.0% 1.71 US$4,946
2025-03-05 2025-03-04 S Sale
4.3
O'Neill Gilmore Neil

CEO

Executive Director
16,632 -5.3%
1.71
US$28,452 		16,632 -5.3% 1.71 US$28,452
2025-03-05 2025-03-04 S Sale
3.7
Lucera Erick

EVP, CHIEF FINANCIAL OFFICER

Officer
4,109 -3.5%
1.71
US$7,030 		4,109 -3.5% 1.71 US$7,030
2025-02-28 2025-03-03 PrS Proposed sale
4.3
O'Neill Gilmore Neil

Officer; Director

Executive Director
35,000
1.86
US$65,100 		35,000 1.86 US$65,100
2025-02-28 2025-03-03 PrS Proposed sale
3.7
Lucera Erick

Officer

Officer
8,000
1.86
US$14,880 		8,000 1.86 US$14,880
2025-02-28 2025-03-03 PrS Proposed sale
4.1
Burkly Linda

Officer

Officer
6,000
1.86
US$11,160 		6,000 1.86 US$11,160
2024-12-05 2024-12-03 S Sale
4.3
O'Neill Gilmore Neil

CEO

Executive Director
1,618 -0.5%
2.08
US$3,361 		1,618 -0.5% 2.08 US$3,361
2024-12-05 2024-12-03 S Sale
4.4
Mei Baisong

EVP, CHIEF MEDICAL OFFICER

Officer
541 -0.4%
2.08
US$1,124 		541 -0.4% 2.08 US$1,124
2024-09-06 2024-09-04 S Sale
4.4
Mei Baisong

EVP, CHIEF MEDICAL OFFICER

Officer
518 -0.4%
3.42
US$1,774 		518 -0.4% 3.42 US$1,774
2024-09-06 2024-09-04 S Sale
4.3
O'Neill Gilmore Neil

CEO

Executive Director
1,555 -0.5%
3.42
US$5,325 		1,555 -0.5% 3.42 US$5,325
2024-08-29 2024-09-03 PrS Proposed sale
4.3
O'Neill Gilmore Neil

Officer; Director

Executive Director
3,000
3.92
US$11,760 		3,000 3.92 US$11,760
2024-08-29 2024-09-03 PrS Proposed sale
4.4
Mei Baisong

Officer

Officer
1,000
3.92
US$3,920 		1,000 3.92 US$3,920
2024-07-26 2024-07-25 S Sale
4.1
Burkly Linda

EVP, CHIEF SCIENTIFIC OFFICER

Officer
11,886 -14.0%
5.42
US$64,370 		11,886 -14.0% 5.42 US$64,370
2024-07-18 2024-07-25 PrS Proposed sale
4.1
Burkly Linda

Officer

Officer
26,000
5.61
US$145,860 		26,000 5.61 US$145,860
2024-07-22 2024-07-19 S Sale
4.4
Mei Baisong

EVP, CHIEF MEDICAL OFFICER

Officer
6,619 -4.7%
5.21
US$34,456 		6,619 -4.7% 5.21 US$34,456
2024-07-18 2024-07-19 PrS Proposed sale
4.4
Mei Baisong

Officer

Officer
14,000
5.61
US$78,540 		14,000 5.61 US$78,540
2024-06-06 2024-06-04 S Sale
4.4
Mei Baisong

EVP, CHIEF MEDICAL OFFICER

Officer
511 -0.4%
5.50
US$2,808 		511 -0.4% 5.50 US$2,808
2024-06-06 2024-06-04 S Sale
4.3
O'Neill Gilmore Neil

CEO

Executive Director
12,191 -3.7%
5.50
US$66,997 		12,191 -3.7% 5.50 US$66,997
2024-05-31 2024-06-03 PrS Proposed sale
4.3
O'Neill Gilmore Neil

Officer; Director

Executive Director
24,000
5.32
US$127,680 		24,000 5.32 US$127,680
2024-05-31 2024-06-03 PrS Proposed sale
4.4
Mei Baisong

Officer

Officer
1,000
5.32
US$5,320 		1,000 5.32 US$5,320
2024-05-22 2024-05-20 S Sale
3.7
Lucera Erick

EVP, CHIEF FINANCIAL OFFICER

Officer
22,337 -16.1%
5.61
US$125,404 		22,337 -16.1% 5.61 US$125,404
2024-05-17 2024-05-17 PrS Proposed sale
3.7
Lucera Erick

Officer

Officer
45,000
5.71
US$256,950 		45,000 5.71 US$256,950
2024-05-14 2024-05-13 B Purchase
3.2
Hopfield Jessica
Non-Executive Director
45,000 +198.2%
5.64
US$253,868 		45,000 +198.2% 5.64 US$253,868
2024-05-14 2024-05-13 B Purchase
3.2
Hopfield Jessica
Non-Executive Director
45,000 +198.2%
5.64
US$253,868 		45,000 +198.2% 5.64 US$253,868
2024-03-05 2024-03-05 S Sale
4.3
O'Neill Gilmore Neil

CEO

Executive Director
77,824 -19.2%
9.42
US$732,884 		77,824 -19.2% 9.42 US$732,884
2024-03-05 2024-03-04 S Sale
4.4
Mei Baisong

SVP, CHIEF MEDICAL OFFICER

Officer
20,327 -12.6%
9.42
US$191,425 		20,327 -12.6% 9.42 US$191,425
2024-03-04 2024-03-04 PrS Proposed sale
4.3
O'Neill Gilmore Neil

Officer; Director

Executive Director
140,000
8.86
US$1,240,400 		140,000 8.86 US$1,240,400
2023-12-07 2023-12-05 S Sale
3.8
Eaton Bruce

EVP, CBO AND CTO

Officer
103 -0.1%
10.90
US$1,122 		103 -0.1% 10.90 US$1,122
2023-11-16 2023-11-14 S Sale
3.8
Eaton Bruce

EVP, CBO AND CTO

Officer
695 -0.9%
8.21
US$5,706 		695 -0.9% 8.21 US$5,706
2023-11-09 2023-11-07 S Sale
3.8
Eaton Bruce

EVP, CBO AND CTO

Officer
139 -0.2%
8.40
US$1,168 		139 -0.2% 8.40 US$1,168
2023-09-07 2023-09-06 S Sale
3.8
Eaton Bruce

EVP, CBO AND CTO

Officer
103 -0.1%
8.82
US$908 		103 -0.1% 8.82 US$908
2023-08-15 2023-08-11 S Sale
3.8
Eaton Bruce

EVP, CBO AND CTO

Officer
702 -0.9%
8.59
US$6,033 		702 -0.9% 8.59 US$6,033
2023-08-10 2023-08-08 S Sale
3.8
Eaton Bruce

EVP, CBO AND CTO

Officer
141 -0.2%
8.39
US$1,183 		141 -0.2% 8.39 US$1,183
2023-07-21 2023-07-19 S Sale
4.4
Mei Baisong

SVP, CHIEF MEDICAL OFFICER

Officer
4,317 -5.7%
8.80
US$37,990 		4,317 -5.7% 8.80 US$37,990
2023-06-07 2023-06-05 S Sale
3.8
Eaton Bruce

EVP, CBO AND CTO

Officer
105 -0.1%
9.50
US$998 		105 -0.1% 9.50 US$998
2023-06-07 2023-06-05 S Sale
4.3
O'Neill Gilmore Neil

CEO

Executive Director
6,486 -4.7%
9.50
US$61,638 		6,486 -4.7% 9.50 US$61,638
2023-06-02 2023-06-05 PrS Proposed sale
4.3
Gilmore Neil O'Neill

Officer; Director

Executive Director
8,500
9.18
US$78,030 		8,500 9.18 US$78,030
2023-05-15 2023-05-11 S Sale
4.1
ROBERTSON MICHELLE

EVP, CHIEF FINANCIAL OFFICER

Officer
949 -0.9%
9.87
US$9,369 		949 -0.9% 9.87 US$9,369
2023-05-15 2023-05-11 S Sale
3.8
Eaton Bruce

EVP, CBO AND CTO

Officer
668 -0.9%
9.87
US$6,594 		668 -0.9% 9.87 US$6,594
2023-05-11 2023-05-11 PrS Proposed sale
4.1
Michelle Robertson

Officer

Officer
3,000
3.62
US$10,845 		3,000 3.62 US$10,845
2023-05-11 2023-05-09 S Sale
3.8
Eaton Bruce

EVP, CBO AND CTO

Officer
135 -0.2%
9.51
US$1,284 		135 -0.2% 9.51 US$1,284
2023-03-06 2023-03-03 S Sale
4.1
ROBERTSON MICHELLE

EVP, CHIEF FINANCIAL OFFICER

Officer
184 -0.2%
8.89
US$1,636 		184 -0.2% 8.89 US$1,636
2023-03-06 2023-03-03 S Sale
3.8
Eaton Bruce

EVP, CBO AND CTO

Officer
101 -0.1%
8.89
US$898 		101 -0.1% 8.89 US$898
2023-02-15 2023-02-13 S Sale
3.8
Eaton Bruce

EVP, CBO AND CTO

Officer
3,307 -5.1%
9.67
US$31,963 		3,307 -5.1% 9.67 US$31,963
2023-02-15 2023-02-13 S Sale
4.1
ROBERTSON MICHELLE

EVP, CHIEF FINANCIAL OFFICER

Officer
4,287 -5.3%
9.67
US$41,435 		4,287 -5.3% 9.67 US$41,435
2023-02-15 2023-02-13 S Sale
1.2
Shearman Mark S

EVP, CHIEF SCIENTIFIC OFFICER

Officer
2,790 -4.1%
9.67
US$26,966 		2,790 -4.1% 9.67 US$26,966
2023-02-09 2023-02-07 S Sale
3.8
Eaton Bruce

EVP, CBO AND CTO

Officer
346 -0.5%
11.10
US$3,841 		346 -0.5% 11.10 US$3,841
2023-01-12 2023-01-10 S Sale
4.1
ROBERTSON MICHELLE

EVP, CHIEF FINANCIAL OFFICER

Officer
1,752 -2.1%
8.16
US$14,296 		1,752 -2.1% 8.16 US$14,296
2022-12-06 2022-12-05 S Sale
3.8
Eaton Bruce

EVP, CHIEF BUSINESS OFFICER

Officer
102 -0.2%
10.23
US$1,043 		102 -0.2% 10.23 US$1,043
Explore more

More insider trading research around Editas Medicine Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America